Verrica Pharmaceuticals Stock Investor Sentiment

VRCA Stock  USD 0.99  0.01  1.00%   
About 57% of all Verrica Pharmaceuticals' investors are looking to take a long position. The analysis of overall sentiment of trading Verrica Pharmaceuticals stock suggests that some investors are interested at this time. The current market sentiment, together with Verrica Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Verrica Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  

Verrica Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Verrica Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at investing.com         
Jefferies lifts Verrica Pharmaceuticals shares target on strong Ycanth prescription growth
Investing News at Macroaxis
over six months ago at investing.com         
Verrica stock PT raised to 14 by H.C. Wainwright on strong YCANTH sales
Investing News at Macroaxis
over six months ago at globenewswire.com         
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over six months ago at seekingalpha.com         
Verrica Pharmaceuticals Non-GAAP EPS of -0.38 beats by 0.06, revenue of 3.83M beats by 1.18M
seekingalpha News
over six months ago at gurufocus.com         
Verrica Pharmaceuticals Inc Reports Q1 2024 Results A Detailed Financial Review
Gurufocus Stories at Macroaxis
over six months ago at investorplace.com         
VRCA Stock Earnings Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
sbwire news
over six months ago at globenewswire.com         
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
Macroaxis News: globenewswire.com
over six months ago at zacks.com         
Xeris Biopharma Reports Q1 Loss, Lags Revenue Estimates
zacks News
over six months ago at simplywall.st         
Verrica Pharmaceuticals Inc. adds US32m in market cap and insiders have a 38 percent stake in that g...
Simply Wall St News at Macroaxis
over six months ago at benzinga.com         
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Result...
benzinga news
over six months ago at zacks.com         
Aquestive Therapeutics Reports Q1 Loss, Misses Revenue Estimates
zacks News
over six months ago at finance.yahoo.com         
Verrica Pharmaceuticals Moves 7.4 percent Higher Will This Strength Last?
Yahoo News
over six months ago at zacks.com         
Verrica Pharmaceuticals Moves 7.4 percent Higher Will This Strength Last?
zacks News
over six months ago at news.google.com         
Verrica Pharmaceuticals Inc. Upgraded to Strong Buy What Does It Mean for the Stock - Yahoo Singapor...
Google News at Macroaxis
over six months ago at benzinga.com         
Bragar Eagel Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstu...
benzinga news
Far too much social signal, news, headlines, and media speculation about Verrica Pharmaceuticals that are available to investors today. That information is available publicly through Verrica media outlets and privately through word of mouth or via Verrica internal channels. However, regardless of the origin, that massive amount of Verrica data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verrica Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verrica Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verrica Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verrica Pharmaceuticals alpha.

Verrica Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Prygocki Mark A Sr of 20000 shares of Verrica Pharmaceuticals at 8.78 subject to Rule 16b-3
09/10/2024
2
Disposition of 2675611 shares by Manning Paul B of Verrica Pharmaceuticals subject to Rule 16b-3
09/19/2024
3
Verrica Pharmaceuticals CFO resigns to pursue new opportunity - Investing.com
09/27/2024
4
Verrica Pharmaceuticals to lay off about half of its staff in restructuring
10/02/2024
5
Verrica downgraded to hold by Needham, cash position cited
10/03/2024
6
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
10/08/2024
7
Verrica Pharmaceuticals Price Target Lowered to 10.00 at TD Cowen
10/21/2024
8
Insider Trading
11/05/2024
9
This Super Micro Computer Analyst Turns Bearish Here Are Top 5 Upgrades For Wednesday
11/06/2024
10
Verrica Announces Pricing of 42.0 Million Public Offering
11/21/2024

Complementary Tools for Verrica Stock analysis

When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences